Full history for every metric is available with a Kvantra account
Sio Gene Therapies Inc. (SIOX)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -72 | -30 | |||||
| Net profit | $m | -181 | -222 | -129 | -73 | -32 | -72 | -28 |
| EPS reported | $ | -0.98 | -0.38 | |||||
| Operating cashflow per share | $ | -0.82 | -0.82 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -0.83 | -0.83 | |||||
| Free cash flow | $m | -61 | -37 | |||||
| Net debt | $m | -61 | -46 | |||||
| Book value equity | $m | 60 | 45 | |||||
| Book value per share | $ | 0.82 | 0.61 | |||||
| Number of shares | m | 73.21 | 73.98 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.81 | 0.78 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.80 | -0.94 | |||||
| EV/EBITDA LTM | x | 0.17 | 0.37 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -146.55% | -205.42% | |||||
| FCF Yield | % | -124.44% | -105.90% | |||||
| Quality | ||||||||
| ROE | % | -119.12% | -78.26% | |||||
| ROIC | % | -114.96% | -114.96% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -24.26 | - | |||||
| Net Debt/EBITDA | x | 0.86 | 0.86 | |||||
| EBIT/Net interest | x | -2,676.56 | -2,676.56 | |||||
| Net debt/market cap | % | -124.79% | -130.45% | |||||
| Net debt/Equity | x | -1.01 | -1.02 | |||||
| Gross debt/equity | x | 0.04 | 0.00 | |||||
Company overview
Sio Gene Therapies Inc. is a biotechnology company in the clinical development phase, committed to pioneering gene therapies designed to fundamentally alter the prognosis for patients afflicted with neurodegenerative conditions. Its therapeutic pipeline is supported by strategic licensing agreements, including one with Oxford BioMedica (UK) Ltd. for the advancement and market introduction of AXO-Lenti-PD and associated gene therapy offerings. Furthermore, Sio Gene Therapies collaborates with The University of Massachusetts Medical School on the development and commercialization of other gene therapy candidates, notably AXO-AAV-GM1 and AXO-AAV-GM. Incorporated in 2014 and headquartered in New York, New York, the entity was known as Axovant Gene Therapies Ltd. prior to its renaming in November 2020.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Sio Gene Therapies Inc. (SIOX)
Sio Gene Therapies Inc. is a biotechnology company in the clinical development phase, committed to pioneering gene therapies designed to fundamentally alter the prognosis for patients afflicted with neurodegenerative conditions. Its therapeutic pipeline is supported by strategic licensing agreements, including one with Oxford BioMedica (UK) Ltd. for the advancement and market introduction of AXO-Lenti-PD and associated gene therapy offerings. Furthermore, Sio Gene Therapies collaborates with The University of Massachusetts Medical School on the development and commercialization of other gene therapy candidates, notably AXO-AAV-GM1 and AXO-AAV-GM. Incorporated in 2014 and headquartered in New York, New York, the entity was known as Axovant Gene Therapies Ltd. prior to its renaming in November 2020.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free